For the Inventor, By the Inventor

Enter assignee name

Bridgewater, NJ, United States of America

Targegen, Inc.

USPTO Granted Patents = 13

% Expired Patents = 38.5

EPO Patents = 3

Forward Citations = 453

Loading Chart...

Loading Chart...

19 inventors (with patents filed for the assignee):

Glenn Noronha (10 out of 16 patents)

John Hood (8 out of 123 patents)

Elena Dneprovskaia (8 out of 11 patents)

4. Chi Ching Mak (7 out of 34 patents)

5. Richard M Soll (7 out of 71 patents)

6. Wolfgang J Wrasidlo (6 out of 52 patents)

7. Jianguo Cao (6 out of 84 patents)

8. Joel Renick (6 out of 10 patents)

9. Andrew McPherson (6 out of 6 patents)

10. Binqi Zeng (6 out of 6 patents)

11. Ved Prakash Pathak (6 out of 9 patents)

12. Ute Splittgerber (3 out of 4 patents)

13. Colleen Gritzen (3 out of 3 patents)

14. Ningning Zhao (3 out of 3 patents)

15. Daniel L Lohse (3 out of 3 patents)

13 patents: Sort by Forward Citations

1. 8604042 - Bi-aryl meta-pyrimidine inhibitors of kinases (2013-12-10),

2. 8481536 - Benzotriazine inhibitors of kinases (2013-07-09),

3. 8372971 - Heterocyclic compounds and methods of use (2013-02-12),

4. 8138199 - Use of bi-aryl meta-pyrimidine inhibitors of kinases (2012-03-20),

5. 8133900 - Use of bi-aryl meta-pyrimidine inhibitors of kinases (2012-03-13),

6. 8084618 - Heterocyclic compounds and methods of use (2011-12-27),

7. 8030487 - 2-amino—5-substituted pyrimidine inhibitors (2011-10-04),

8. 7825246 - Bi-aryl meta-pyrimidine inhibitors of kinases (2010-11-02),

9. 7691858 - Kinase inhibitors and methods of use thereof (2010-04-06),

10. 7652051 - Heterocyclic compounds and methods of use (2010-01-26),

11. 7528143 - Bi-aryl meta-pyrimidine inhibitors of kinases (2009-05-05),

12. 7456176 - Benzotriazine inhibitors of kinases (2008-11-25),

13. 7208493 - Vasculostatic agents and methods of use thereof (2007-04-24),

TargeGen, Inc. is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for the treatment of diseases. With a strong emphasis on precision medicine, TargeGen aims to create targeted therapies that address unmet medical needs. To achieve this, the company employs cutting-edge technologies and collaborates with leading research institutions and industry partners. Through their innovative approach, TargeGen strives to improve patients' lives and make a significant impact in the field of medicine.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

13 Patents

#20 in Bridgewater, NJ

#896 in New Jersey

#23,808 in US

#44,950 in the World

Bridgewater, NJ, United States of America

Targegen, Inc.

Forward Citations = 453

19 inventors:

Glenn Noronha (10 out of 16 patents)

John Hood (8 out of 123 patents)

Elena Dneprovskaia (8 out of 11 patents)

4. Chi Ching Mak (7 out of 34 patents)

5. Richard M Soll (7 out of 71 patents)

Please report any incorrect information to [email protected]

Loading…